1. Home
  2. BNBX vs GOVX Comparison

BNBX vs GOVX Comparison

Compare BNBX & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BNBX

Applied DNA Sciences Inc.

N/A

Current Price

$0.78

Market Cap

4.3M

ML Signal

N/A

Logo GeoVax Labs Inc.

GOVX

GeoVax Labs Inc.

N/A

Current Price

$1.93

Market Cap

4.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BNBX
GOVX
Founded
1983
2001
Country
United States
United States
Employees
26
17
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.3M
4.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BNBX
GOVX
Price
$0.78
$1.93
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$200.00
AVG Volume (30 Days)
63.7K
129.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$253.12
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.61
$0.12
52 Week High
$6.17
$4.40

Technical Indicators

Market Signals
Indicator
BNBX
GOVX
Relative Strength Index (RSI) 37.65 52.43
Support Level N/A $0.55
Resistance Level $0.85 $4.40
Average True Range (ATR) 0.08 0.16
MACD 0.04 0.02
Stochastic Oscillator 55.05 93.06

Price Performance

Historical Comparison
BNBX
GOVX

About BNBX Applied DNA Sciences Inc.

BNB Plus Corp focuses on digital asset treasury management of BNB. The group is unlocking institutional-grade access to the Binance ecosystem, delivering non-directional yield strategies and long BNB exposure, powering the future of blockchain through a transparent, actively managed BNB treasury. The Company's differentiated blends sophisticated DeFi yield generation with Binance-native opportunities, unlocking access to high-performance digital assets for investors traditionally excluded from the space.

About GOVX GeoVax Labs Inc.

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.

Share on Social Networks: